Menu
Search
|

Menu

Close
X

Mustang Bio Inc MBIO.OQ (NASDAQ Stock Exchange Global Market)

6.68 USD
-0.18 (-2.62%)
As of 4:00 PM EDT
chart
Previous Close 6.86
Open 6.85
Volume 77,083
3m Avg Volume 25,323
Today’s High 7.00
Today’s Low 6.21
52 Week High 13.25
52 Week Low 6.21
Shares Outstanding (mil) 27.11
Market Capitalization (mil) 193.85
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.238
FY17
-1.207
FY16
-0.502
FY15
-0.065
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.04
Price to Sales (TTM)
vs sector
3,877.07
8.22
Price to Book (MRQ)
vs sector
3.34
4.29
Price to Cash Flow (TTM)
vs sector
--
22.60
Total Debt to Equity (MRQ)
vs sector
0.00
17.61
LT Debt to Equity (MRQ)
vs sector
0.00
13.12
Return on Investment (TTM)
vs sector
-52.86
13.11
Return on Equity (TTM)
vs sector
-52.91
15.11

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2 Gansevoort St Fl 9
NEW YORK   NY   10014-1667

Phone: +1781.6524507

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology, which uses the patient’s own T cells to engage and destroy specific tumors. The Company, through its agreement with City of Hope National Medical Center, is using three novel CAR T therapies in the development of cancer treatments, including human epidermal growth factor receptor 2 CAR T technology, CS1-specific CAR T technology, and prostate stem cell antigen CAR T technology.

SPONSORED STORIES